Please note that Epadel is sold by Mochida Pharm.
If you read "The Mochida Pharmaceutical Group,"12-14 Medium Term Plan" issued on April 2,2012 (Google Search)--you will note that Mochida is pushing Epadel and pushing publicity for JELIS Trials.
Takeda has nothing to do with Epadel-- So they can sell what they want.
But Mochida has launched a publicity campaign in Japan-stating that EPADEL is the ONLY scientific study done in Japan to prove the benefits.(Indirectly telling Japanese that other competitors have NOT proven any Cardiovascular benefits--that includes LOVAZA. So Takeda will have tough time brain washing Japanese who are highly educated.
They KNOW that Lovaza is superior, if not they would not spend huge resources introducing it to Japan, they are not playing "fantasy games" as you idi*ts on this board.
But if there was any money to be made selling pure EPA, Takeda could have licensed it from Mochida basically for free for worldwide sales and if the potential was just a fraction of what you pumpers believe they would have run with pure EPA and basically laughed at Lovaza!
But INSTEAD they are introducing Lovaza to JAPAN, if you don't understand what this really mean, you must be a retard, pure and simple.